Shifting the Paradigm of Type 1 Diabetes: A Narrative Review of Disease-Modifying Therapies
Author Information
Author(s): O’Donovan Alexander J., Gorelik Seth, Nally Laura M.
Primary Institution: Yale University School of Medicine
Hypothesis
Advancements in therapies that can delay the onset of clinical type 1 diabetes are crucial.
Conclusion
The review highlights the potential of various disease-modifying therapies to delay the progression of type 1 diabetes.
Supporting Evidence
- Teplizumab is the first drug approved by the FDA to delay the progression from stage 2 to stage 3 type 1 diabetes.
- Studies show that teplizumab can preserve beta cell function and reduce insulin requirements in patients with type 1 diabetes.
- Various therapies are being studied to intervene at different stages of type 1 diabetes to improve health outcomes.
Takeaway
This study looks at new treatments that can help kids with type 1 diabetes not get sick as fast. It's like finding ways to keep them healthy for longer.
Methodology
A comprehensive literature review was conducted using PubMed and ClinicalTrials.gov to identify published trials and ongoing research on disease-modifying therapies in type 1 diabetes.
Limitations
The review may not cover all ongoing studies due to the rapidly evolving nature of research in this field.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website